MDS e-News: October 2019
For almost eight years, this has been Brian Merrick’s greeting when entering the treatment room in Melbourne for his monthly round of azacitidine (Vidaza®) injections on a clinical trial.
When someone with MDS is treated with azacitidine (Vidaza®), it takes six months to find out if they are responding to the drug. Dr Unnikrishnan is working to change that.
The landmark report, State of the Nation: Blood Cancer in Australia, was released by the Leukaemia Foundation last month includes opportunities for improvement in treatment and care for MDS.
More than 600 Australians have a potentially life-saving stem cell transplant each year and of those needing a matched unrelated donor, more than 80% of their donors are sourced overseas.